Beranda › Kanker Metastatik › California › Mountain View
Uji klinis Kanker Metastatik di Mountain View, CA
25 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Mountain View (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Menerima pesertaFase 2
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi jauhnya
- VA Palo Alto Health Care System, Palo Alto · 5 mi jauhnya
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Menerima pesertaFase 1/2
- Stanford, Palo Alto · 5 mi jauhnya
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Menerima pesertaFase 2/3
- Stanford Cancer Center, Palo Alto · 5 mi jauhnya
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Menerima pesertaFase 3
- Palo Alto Medical Foundation - Palo Alto Center, Palo Alto · 5 mi jauhnya
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Menerima pesertaFase 1/2
- Stanford Medicine, Palo Alto · 5 mi jauhnya
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Menerima pesertaFase 1
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- Stanford University Medical Center, Stanford · 5 mi jauhnya
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Menerima pesertaFase 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi jauhnya
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Menerima pesertaFase 3
- Stanford Cancer Center, Palo Alto · 5 mi jauhnya
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Menerima pesertaFase 2
- Stanford University, Palo Alto · 5 mi jauhnya
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Menerima pesertaFase 3
- Research Site, Palo Alto · 5 mi jauhnya
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Menerima pesertaFase 1/2
- Stanford Cancer Institute (SCI), Stanford · 5 mi jauhnya
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- Stanford Medicine Cancer Center, Stanford · 5 mi jauhnya
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Stanford Cancer Institute, Stanford University, Palo Alto · 5 mi jauhnya
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Menerima pesertaFase 3
- Stanford University School of Medicine, Palo Alto · 5 mi jauhnya
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Stanford Medicine Cancer Center, Stanford · 5 mi jauhnya
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Menerima pesertaFase 1/2
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Menerima pesertaFase 2/3
- Stanford Health Care - Skin Cancer Program, Stanford · 5 mi jauhnya
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Menerima pesertaFase 2/3
- Stanford Cancer Institute, Palo Alto · 5 mi jauhnya
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Menerima pesertaFase 1
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Menerima pesertaFase 1
- Stanford Cancer Institute, Stanford · 5 mi jauhnya
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
Menerima pesertaStudi observasional
- VA Palo Alto Healthcare System, Palo Alto · 5 mi jauhnya
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Menerima pesertaFase 1
- Stanford Cancer Institute, Palo Alto · 5 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Stanford · 5 mi jauhnya
Uji klinis Kanker Metastatik di kota lain
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Studi lain di Mountain View
- Kanker (semua jenis)40 studi
- Kanker Payudara26 studi
- Kanker Paru Non-Sel Kecil21 studi
- Leukemia Mieloid Akut19 studi
- Kanker Ovarium19 studi
- Gangguan Spektrum Autisme17 studi
- Kanker Paru17 studi
- Kanker Prostat15 studi
- Gagal Jantung15 studi
- Autisme13 studi
- Leukemia Limfoblastik Akut13 studi
- Kanker Kolorektal13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.